NANOS2

Summary

NANOS2 (nanos C2HC-type zinc finger 2, HGNC:23292) is a protein-coding gene on chromosome 19q13.32, encoding Nanos homolog 2 (P60321). Plays a key role in the sexual differentiation of germ cells by promoting the male fate but suppressing the female fate.

Enables enzyme activator activity. Involved in mRNA destabilization and negative regulation of translation. Located in nucleus and perinuclear region of cytoplasm.

Source: NCBI Gene 339345 — RefSeq curated summary.

At a glance

• Gene–disease (curated): schizophrenia (No Known Disease Relationship, GenCC)
• GWAS associations: 19
• Clinical variants (ClinVar): 239 total
• MANE Select transcript: NM_001029861

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:23292
Approved symbol	NANOS2
Name	nanos C2HC-type zinc finger 2
Location	19q13.32
Locus type	gene with protein product
Status	Approved
Aliases	NOS2
Ensembl gene	ENSG00000188425
Ensembl biotype	protein_coding
OMIM	608228
Entrez	339345

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000341294

RefSeq mRNA: 1 — MANE Select: NM_001029861 NM_001029861

CCDS: CCDS33056

Canonical transcript exons

ENST00000341294 — 1 exons

Exon	Start	End
ENSE00001374579	45913214	45914778

Expression profiles

Bgee: expression breadth broad, 32 present calls, max score 80.69.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.0056 / max 2.8991, expressed in 3 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
181589	0.0056	3

Top tissues by expression

236 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	80.69	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	75.78	gold quality
right testis	UBERON:0004534	61.98	gold quality
left testis	UBERON:0004533	61.27	gold quality
testis	UBERON:0000473	60.93	gold quality
amniotic fluid	UBERON:0000173	46.25	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	43.37	gold quality
secondary oocyte	CL:0000655	42.57	gold quality
vastus lateralis	UBERON:0001379	41.41	gold quality
quadriceps femoris	UBERON:0001377	41.37	gold quality
middle temporal gyrus	UBERON:0002771	41.37	gold quality
superficial temporal artery	UBERON:0001614	41.33	gold quality
palpebral conjunctiva	UBERON:0001812	41.10	gold quality
mucosa of paranasal sinus	UBERON:0005030	40.98	gold quality
jejunal mucosa	UBERON:0000399	40.59	gold quality
biceps brachii	UBERON:0001507	40.57	gold quality
epithelium of nasopharynx	UBERON:0001951	40.45	gold quality
myocardium	UBERON:0002349	40.45	gold quality
gingival epithelium	UBERON:0001949	40.43	gold quality
germinal epithelium of ovary	UBERON:0001304	40.33	gold quality
esophagus squamous epithelium	UBERON:0006920	40.29	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	40.27	gold quality
jejunum	UBERON:0002115	40.18	gold quality
cortical plate	UBERON:0005343	40.16	gold quality
cartilage tissue	UBERON:0002418	40.06	gold quality
oviduct epithelium	UBERON:0004804	40.03	gold quality
mammary duct	UBERON:0001765	39.98	gold quality
mucosa of sigmoid colon	UBERON:0004993	39.95	gold quality
deltoid	UBERON:0001476	39.83	gold quality
saphenous vein	UBERON:0007318	39.83	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.28

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

32 targeting NANOS2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-6768-5P	99.92	67.36	1942
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-6756-5P	99.82	67.97	2466
HSA-MIR-6766-5P	99.68	67.70	2325
HSA-MIR-10394-5P	99.65	66.83	1852
HSA-MIR-1205	99.65	66.76	1826
HSA-MIR-762	99.58	66.61	1994
HSA-MIR-12123	99.52	71.79	2990
HSA-MIR-766-5P	99.47	67.91	2225
HSA-MIR-4498	99.47	67.42	2360
HSA-MIR-1275	99.47	67.90	2749
HSA-MIR-942-5P	99.41	68.40	1977
HSA-MIR-7109-5P	99.18	66.13	1057
HSA-MIR-4478	99.07	65.16	2320
HSA-MIR-5001-5P	99.05	66.76	1972
HSA-MIR-4724-5P	98.87	67.75	1324
HSA-MIR-6829-5P	98.86	65.12	1480
HSA-MIR-4656	98.79	66.22	1306
HSA-MIR-4635	98.74	67.63	1339
HSA-MIR-210-5P	98.57	64.37	832
HSA-MIR-4290	98.51	65.17	907
HSA-MIR-4483	98.09	64.12	1642
HSA-MIR-637	97.91	64.05	1517
HSA-MIR-10397-5P	97.31	69.06	710
HSA-MIR-152-5P	96.42	66.59	960
HSA-MIR-4749-3P	96.40	66.24	798
HSA-MIR-6805-5P	95.79	64.86	670
HSA-MIR-1256	95.44	66.33	784
HSA-MIR-3131	95.33	65.74	102

Literature-anchored findings (GeneRIF, showing 4)

• The increased NO production with increased expression of iNOS and ncNOS may contribute to the pathological and physiological features of UVB-induced erythema and skin inflammation. (PMID:14615895)
• Data describe for the first time the expression pattern of the NANOS2 gene in human tissues and show that it is testis specific. We found that NANOS2 protein is present in prenatal germ cells and at later stages in spermatogenesis. (PMID:19168545)
• We conclude that heterogeneous population of the HEK293T cells might be easily shifted towards expression of the pluripotency markers by ectopic expression of the SON factors or by growth in serum depleted media. (PMID:27794480)
• A cooperative mechanism of target RNA selection via germ-cell-specific RNA-binding proteins NANOS2 and DND1. (PMID:35705038)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	nanos2	ENSDARG00000116802
mus_musculus	Nanos2	ENSMUSG00000051965
rattus_norvegicus	Nanos2	ENSRNOG00000074804
drosophila_melanogaster	nanos	FBGN0002962
caenorhabditis_elegans		WBGENE00003783
caenorhabditis_elegans		WBGENE00003784

Paralogs (2): NANOS3 (ENSG00000187556), NANOS1 (ENSG00000188613)

Protein

Protein identifiers

Nanos homolog 2 — P60321 (reviewed: P60321)

All UniProt accessions (1): P60321

UniProt curated annotations — full annotation on UniProt →

Function. Plays a key role in the sexual differentiation of germ cells by promoting the male fate but suppressing the female fate. Represses the female fate pathways by suppressing meiosis, which in turn results in the promotion of the male fate. Maintains the suppression of meiosis by preventing STRA8 expression, which is required for premeiotic DNA replication, after CYP26B1 is decreased. Regulates the localization of the CCR4-NOT deadenylation complex to P-bodies and plays a role in recruiting the complex to trigger the degradation of mRNAs involved in meiosis. Required for the maintenance of the spermatogonial stem cell population. Not essential for the assembly of P-bodies but is required for the maintenance of their normal state.

Subunit / interactions. Interacts with CNOT1, CNOT3, CNOT6L, CNOT7 and CNOT9.

Subcellular location. Cytoplasm. P-body. Perinuclear region.

Tissue specificity. Testis and ovary. Expression found in several spermatogenic stages: in cells on the periphery of the tubules which could correspond to spermatogonia, in spermatocytes and in round spermatids (at protein level).

Domain organisation. The Nanos-type zinc finger is composed of two C2HC motifs, each motif binding one molecule of zinc. It is essential for the translation repression activity of the protein.

Similarity. Belongs to the nanos family.

RefSeq proteins (1): NP_001025032* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR008705	Nanos/Xcar2	Family
IPR024161	Znf_nanos-typ	Domain
IPR038129	Nanos_sf	Homologous_superfamily

Pfam: PF05741

UniProt features (14 total): binding site 8, short sequence motif 2, chain 1, zinc finger region 1, sequence variant 1, region of interest 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P60321-F1	76.58	0.34

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (8): 101; 109; 114; 63; 66; 79; 90; 98

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 415 (showing top): GOBP_CIRCADIAN_RHYTHM, GOBP_NEGATIVE_REGULATION_OF_REPRODUCTIVE_PROCESS, LEE_NEURAL_CREST_STEM_CELL_DN, MORF_FLT1, REACTOME_INNATE_IMMUNE_SYSTEM, GOBP_REGULATION_OF_BLOOD_PRESSURE, MORF_MSH3, GOBP_CIRCULATORY_SYSTEM_PROCESS, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, GOBP_REGULATION_OF_MRNA_CATABOLIC_PROCESS, GOBP_REGULATION_OF_NUCLEAR_DIVISION, GOBP_INFLAMMATORY_RESPONSE, GOMF_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_PAIRED_DONORS_WITH_INCORPORATION_OR_REDUCTION_OF_MOLECULAR_OXYGEN, GOBP_POSITIVE_REGULATION_OF_INTERLEUKIN_8_PRODUCTION, GOBP_RESPONSE_TO_PEPTIDE

GO Biological Process (9): mRNA catabolic process (GO:0006402), spermatogenesis (GO:0007283), negative regulation of translation (GO:0017148), germ-line stem cell population maintenance (GO:0030718), negative regulation of meiotic nuclear division (GO:0045835), oogenesis (GO:0048477), mRNA destabilization (GO:0061157), regulation of translation (GO:0006417), cell differentiation (GO:0030154)

GO Molecular Function (6): mRNA binding (GO:0003729), enzyme activator activity (GO:0008047), zinc ion binding (GO:0008270), RNA binding (GO:0003723), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (4): P-body (GO:0000932), nucleus (GO:0005634), cytoplasm (GO:0005737), perinuclear region of cytoplasm (GO:0048471)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
negative regulation of gene expression	3
translation	2
cellular anatomical structure	2
RNA catabolic process	1
mRNA metabolic process	1
developmental process involved in reproduction	1
male gamete generation	1
regulation of translation	1
negative regulation of protein metabolic process	1
stem cell population maintenance	1
negative regulation of cell cycle process	1
regulation of meiotic nuclear division	1
negative regulation of meiotic cell cycle	1
negative regulation of nuclear division	1
meiotic nuclear division	1
germ cell development	1
female gamete generation	1
regulation of mRNA stability	1
RNA destabilization	1
positive regulation of mRNA catabolic process	1
post-transcriptional regulation of gene expression	1
regulation of protein metabolic process	1
cellular developmental process	1
RNA binding	1
catalytic activity	1
enzyme regulator activity	1
molecular function activator activity	1
transition metal ion binding	1
nucleic acid binding	1
binding	1
cation binding	1
cytoplasmic ribonucleoprotein granule	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
cytoplasm	1

Protein interactions and networks

STRING

918 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NANOS2	STRA8	Q7Z7C7	959
NANOS2	CYP26B1	Q9NR63	956
NANOS2	CNOT1	A5YKK6	863
NANOS2	ZBTB16	Q05516	769
NANOS2	DND1	Q8IYX4	767
NANOS2	SYCP3	Q8IZU3	748
NANOS2	DAZL	Q92904	745
NANOS2	GFRA1	P56159	731
NANOS2	SOHLH1	Q5JUK2	687
NANOS2	SOHLH2	Q9NX45	684
NANOS2	DMRT1	Q9Y5R6	659
NANOS2	NEUROG3	Q9Y4Z2	619
NANOS2	BCL6B	Q8N143	618
NANOS2	ID4	P47928	611
NANOS2	DDX4	Q9NQI0	609

IntAct

19 interactions, top by confidence:

A	B	Type	Score
NANOS2	MAGEA12	psi-mi:“MI:0915”(physical association)	0.780
MAGEA12	NANOS2	psi-mi:“MI:0915”(physical association)	0.780
CCNDBP1	NANOS2	psi-mi:“MI:0915”(physical association)	0.670
NANOS2	CCNDBP1	psi-mi:“MI:0915”(physical association)	0.670
NANOS2	S100A10	psi-mi:“MI:0915”(physical association)	0.560
Prdm16	ESYT2	psi-mi:“MI:0914”(association)	0.350
NANOS2	CNOT1	psi-mi:“MI:0914”(association)	0.350
NANOS2	MAGEA12	psi-mi:“MI:0915”(physical association)	0.000
NANOS2	S100A10	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (48): NANOS2 (Two-hybrid), NANOS2 (Two-hybrid), CNOT1 (Affinity Capture-Western), CNOT3 (Affinity Capture-Western), CNOT1 (Reconstituted Complex), CNOT6 (Affinity Capture-MS), CNOT6L (Affinity Capture-MS), CNOT2 (Affinity Capture-MS), TOB2 (Affinity Capture-MS), TNKS1BP1 (Affinity Capture-MS), BTG3 (Affinity Capture-MS), CNOT11 (Affinity Capture-MS), CNOT10 (Affinity Capture-MS), CNOT3 (Affinity Capture-MS), MINK1 (Affinity Capture-MS)

ESM2 similar proteins: A0A1L8HJK9, A9LMC0, B2RVL6, B5DEH0, C3VD30, G5E5X0, O43900, O54880, O95343, P0DH66, P46686, P56163, P58269, P60321, P60322, P60323, P60324, Q07937, Q29RJ0, Q2PFD7, Q38740, Q3UPF5, Q58D79, Q5TKR9, Q5XIX0, Q61103, Q62233, Q6Y2X3, Q705F3, Q768S4, Q7Z2W4, Q80U38, Q8BZ21, Q8CCG1, Q8HXK7, Q8K3Y6, Q8N2G6, Q90WW1, Q90ZZ5, Q90ZZ6

Diamond homologs: E7FDB3, P25724, P60321, P60322, P60323, P60324, Q07937, Q80WY3, Q8WY41, Q90WW1, Q90ZZ5, Q90ZZ6

SIGNOR signaling

4 interactions.

A	Effect	B	Mechanism
“CCR4-NOT complex”	“down-regulates quantity by repression”	NANOS2	“post transcriptional regulation”
NEDD4	“down-regulates quantity by destabilization”	NANOS2	ubiquitination
“Elongin E3-Cul-5”	“down-regulates quantity by destabilization”	NANOS2	polyubiquitination
SPSB2	“down-regulates quantity by destabilization”	NANOS2	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

239 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	167
Likely benign	42
Benign	20

Top pathogenic / likely-pathogenic (0)

SpliceAI

3933 predictions. Top by Δscore:

Variant	Effect	Δscore
17:27758876:TATA:T	donor_loss	1.0000
17:27758878:TA:T	donor_loss	1.0000
17:27758879:A:AG	donor_loss	1.0000
17:27758880:CCT:C	donor_loss	1.0000
17:27759071:TAGAC:T	acceptor_gain	1.0000
17:27759072:AGAC:A	acceptor_gain	1.0000
17:27759073:GAC:G	acceptor_gain	1.0000
17:27759074:AC:A	acceptor_gain	1.0000
17:27759075:CC:C	acceptor_gain	1.0000
17:27759076:C:CC	acceptor_gain	1.0000
17:27759076:C:CG	acceptor_loss	1.0000
17:27759076:C:T	acceptor_gain	1.0000
17:27759083:C:CT	acceptor_gain	1.0000
17:27759083:C:T	acceptor_gain	1.0000
17:27760025:TTTAC:T	donor_loss	1.0000
17:27760028:A:AT	donor_loss	1.0000
17:27760029:CCT:C	donor_loss	1.0000
17:27760175:ACTCC:A	acceptor_loss	1.0000
17:27760176:CTC:C	acceptor_gain	1.0000
17:27760618:CTTA:C	donor_loss	1.0000
17:27760620:TAC:T	donor_loss	1.0000
17:27760621:A:AT	donor_loss	1.0000
17:27760621:AC:A	donor_gain	1.0000
17:27760622:C:A	donor_loss	1.0000
17:27760622:CC:C	donor_gain	1.0000
17:27760745:C:CC	acceptor_gain	1.0000
17:27761138:GCTTA:G	donor_loss	1.0000
17:27761139:CTTA:C	donor_loss	1.0000
17:27761140:TTA:T	donor_loss	1.0000
17:27761141:TA:T	donor_loss	1.0000

AlphaMissense

890 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:45914426:A:G	C90R	0.999
19:45914402:A:G	C98R	0.998
19:45914500:A:G	F65S	0.998
19:45914367:A:C	H109Q	0.997
19:45914367:A:T	H109Q	0.997
19:45914369:G:C	H109D	0.997
19:45914416:A:G	L93P	0.997
19:45914416:A:T	L93Q	0.997
19:45914425:C:G	C90S	0.997
19:45914426:A:T	C90S	0.997
19:45914459:G:C	H79D	0.997
19:45914497:C:G	C66S	0.997
19:45914498:A:T	C66S	0.997
19:45914499:G:C	F65L	0.997
19:45914499:G:T	F65L	0.997
19:45914500:A:C	F65C	0.997
19:45914501:A:G	F65L	0.997
19:45914392:C:G	C101S	0.996
19:45914393:A:G	C101R	0.996
19:45914393:A:T	C101S	0.996
19:45914424:A:C	C90W	0.996
19:45914425:C:T	C90Y	0.996
19:45914457:G:C	H79Q	0.996
19:45914457:G:T	H79Q	0.996
19:45914493:C:A	K67N	0.996
19:45914493:C:G	K67N	0.996
19:45914497:C:T	C66Y	0.996
19:45914506:C:G	C63S	0.996
19:45914507:A:T	C63S	0.996
19:45914371:G:T	A108D	0.995

dbSNP variants (sampled 300 via entrez): RS1000051163 (19:45914120 G>A), RS1000550431 (19:45916193 G>A,T), RS1002045025 (19:45916134 G>A), RS1002811369 (19:45916378 T>A), RS1002863521 (19:45913057 T>G), RS1003161437 (19:45913315 T>C,G), RS1004110482 (19:45915752 A>G), RS1004529023 (19:45915464 T>G), RS1005006938 (19:45916332 G>A), RS1005362849 (19:45916116 TG>T), RS1005679394 (19:45913499 A>C,G), RS1006579789 (19:45913417 T>C,G), RS1006686952 (19:45916672 G>A), RS1007612106 (19:45915127 G>A), RS1009752979 (19:45915084 C>A,T)

Disease associations

OMIM: gene MIM:608228 | disease phenotypes: MIM:611162

GenCC curated gene-disease

Disease	Classification	Inheritance
schizophrenia	No Known Disease Relationship	Unknown

Mondo (2): malaria, susceptibility to (MONDO:0021024), schizophrenia (MONDO:0005090)

Orphanet (1): Malaria (Orphanet:673)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

19 associations (top):

Study	Trait	p-value
GCST000834_6	Psoriasis	4.000000e-11
GCST001729_22	Crohn’s disease	9.000000e-17
GCST002304_14	Fractional exhaled nitric oxide (childhood)	3.000000e-07
GCST002304_20	Fractional exhaled nitric oxide (childhood)	1.000000e-09
GCST002740_55	Inflammatory skin disease	6.000000e-12
GCST002874_12	Psoriasis	6.000000e-10
GCST002874_50	Psoriasis	3.000000e-06
GCST003268_24	Psoriasis vulgaris	3.000000e-13
GCST003269_10	Cutaneous psoriasis	8.000000e-06
GCST003270_12	Psoriatic arthritis	4.000000e-06
GCST005527_18	Psoriasis	3.000000e-16
GCST005529_31	Ankylosing spondylitis	6.000000e-07
GCST005529_4	Ankylosing spondylitis	1.000000e-10
GCST005529_61	Ankylosing spondylitis	1.000000e-08
GCST005537_27	Chronic inflammatory diseases (ankylosing spondylitis, Crohn’s disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)	7.000000e-12
GCST005537_28	Chronic inflammatory diseases (ankylosing spondylitis, Crohn’s disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)	1.000000e-10
GCST007844_9	Ankylosing spondylitis	1.000000e-06
GCST009798_38	Asthma	2.000000e-10
GCST010481_4	Acute anterior uveitis in ankylosing spondylitis	8.000000e-07

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0005536	nitric oxide exhalation measurement
EFO:1001494	psoriasis vulgaris
EFO:0007773	cutaneous psoriasis measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

7 total (human), top 7 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
testosterone-3-carboxymethyloxime-bovine serum albumin conjugate	increases expression	1
bisphenol S	affects cotreatment, decreases methylation	1
Resveratrol	affects cotreatment, decreases expression	1
Fulvestrant	affects cotreatment, decreases methylation	1
Benzo(a)pyrene	affects methylation, increases methylation	1
Plant Extracts	affects cotreatment, decreases expression	1
Valproic Acid	increases methylation	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00000374	PHASE4	COMPLETED	Treatment for First-Episode Schizophrenia
NCT00001656	PHASE4	COMPLETED	Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
NCT00007774	PHASE4	COMPLETED	To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
NCT00014001	PHASE4	COMPLETED	CATIE- Schizophrenia Trial
NCT00018668	PHASE4	COMPLETED	Antipsychotic Response in Schizophrenia
NCT00034801	PHASE4	COMPLETED	Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
NCT00034905	PHASE4	COMPLETED	A Comparison of Seroquel vs. Risperidone in Schizophrenia
NCT00036088	PHASE4	COMPLETED	Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
NCT00044187	PHASE4	COMPLETED	The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
NCT00044655	PHASE4	COMPLETED	Switching Medication to Treat Schizophrenia
NCT00048828	PHASE4	COMPLETED	Treating Drug-Resistant Childhood Schizophrenia
NCT00053703	PHASE4	COMPLETED	Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)
NCT00056498	PHASE4	COMPLETED	Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
NCT00061802	PHASE4	COMPLETED	Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
NCT00080327	PHASE4	COMPLETED	Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
NCT00088049	PHASE4	COMPLETED	Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
NCT00090012	PHASE4	COMPLETED	Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
NCT00100776	PHASE4	COMPLETED	Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
NCT00103571	PHASE4	COMPLETED	Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
NCT00108368	PHASE4	COMPLETED	The Effects of Risperidone and Olanzapine on Thinking
NCT00114595	PHASE4	COMPLETED	Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia
NCT00130923	PHASE4	COMPLETED	Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
NCT00137020	PHASE4	COMPLETED	Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
NCT00140166	PHASE4	COMPLETED	Treatment of Acute Schizophrenia With Vitamin Therapy
NCT00145847	PHASE4	COMPLETED	Naltrexone Treatment of Alcohol Abuse in Schizophrenia
NCT00148564	PHASE4	COMPLETED	Energy Homeostasis Under Treatment With Atypical Antipsychotics
NCT00156715	PHASE4	COMPLETED	Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
NCT00158223	PHASE4	COMPLETED	Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia
NCT00159081	PHASE4	COMPLETED	One Year Drug Treatment in First-Episode Schizophrenia
NCT00159120	PHASE4	COMPLETED	Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
NCT00159133	PHASE4	COMPLETED	Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia
NCT00159757	PHASE4	TERMINATED	12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
NCT00167817	PHASE4	COMPLETED	Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study
NCT00169026	PHASE4	TERMINATED	Alcoholism and Schizophrenia: Effects of Clozapine
NCT00169039	PHASE4	TERMINATED	Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia
NCT00169065	PHASE4	COMPLETED	Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia
NCT00169091	PHASE4	TERMINATED	Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia
NCT00176423	PHASE4	COMPLETED	Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
NCT00176436	PHASE4	COMPLETED	Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients
NCT00177008	PHASE4	COMPLETED	Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety